# A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)

> **NCT03235986** · PHASE2 · TERMINATED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 166 (actual)

## Conditions studied

- Neonatal Respiratory Distress Syndrome

## Interventions

- **DRUG:** nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)
- **DRUG:** nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)
- **OTHER:** nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
- **OTHER:** nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)

## Key facts

- **NCT ID:** NCT03235986
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-28
- **Primary completion:** 2020-05-05
- **Final completion:** 2020-05-05
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** Change in the benefit-risk balance
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235986, "A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03235986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*